Hetero’s Tocilizumab Biosimilar Gets DCGI’s Nod For Treatment Of COVID-19 Patients


New Delhi, September 6: Drug firm Hetero announced that it has received emergency use authorisation from the Drug Controller General of India for its biosimilar version of Tocilizumab for treatment of COVID-19 patients.

Hetero said that it will market the drug under the brand name ‘Tocira’, which will enable medical practitioners to use the drug for the treatment of COVID-19 in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.